Improved survival in ovarian cancer, with widening survival gaps of races and socioeconomic status: a period analysis, 1983-2012
暂无分享,去创建一个
Lewei Yang | Huanhuan Sun | Haiqing Ma | Shuncong Wang | Jinna Wu | Yun Deng | Yan-Qin Yan | Guangwei Yang
[1] T. Akinyemiju,et al. Availability of healthcare resources and epithelial ovarian cancer stage of diagnosis and mortality among Blacks and Whites , 2017, Journal of Ovarian Research.
[2] Samuel D. Towne. Socioeconomic, Geospatial, and Geopolitical Disparities in Access to Health Care in the US 2011–2015 , 2017, International journal of environmental research and public health.
[3] K. Matsuo,et al. Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer , 2016, Obstetrics and gynecology.
[4] S. Vitale,et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis , 2016, Archives of Gynecology and Obstetrics.
[5] A. Whittemore,et al. The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. , 2016, Cancer epidemiology.
[6] N. Bickell,et al. Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995–2008 , 2016, Obstetrics and gynecology.
[7] A. Sauaia,et al. Primary Care Providers Perceptions of Racial/Ethnic and Socioeconomic Disparities in Hypertension Control. , 2015, American journal of hypertension.
[8] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[9] Hongliu Sun,et al. Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010 , 2014, Scientific Reports.
[10] Jason D. Wright,et al. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. , 2014, Gynecologic oncology.
[11] E. Chapman-Davis,et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. , 2014, Gynecologic oncology.
[12] T. Jobo,et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. , 2013, The Lancet. Oncology.
[13] Bernd Holleczek,et al. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[14] M. Doherty,et al. Prognostic impact of marital status on survival of women with epithelial ovarian cancer , 2013, Psycho-oncology.
[15] J. Tracy,et al. Have racial disparities in ovarian cancer increased over time? An analysis of SEER data. , 2012, Gynecologic oncology.
[16] K. Frederiksen,et al. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study , 2009, BMJ : British Medical Journal.
[17] R. Burger,et al. Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.
[18] J. Barnholtz-Sloan,et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. , 2003, American journal of obstetrics and gynecology.
[19] S V Subramanian,et al. Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures--the public health disparities geocoding project. , 2003, American journal of public health.
[20] E. Trimble,et al. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Jarvis T. Chen,et al. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project. , 2002, American journal of epidemiology.
[22] J. Berek,et al. Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.
[23] E. Partridge,et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.
[24] P. Trott,et al. International Classification of Diseases for Oncology , 1977 .
[25] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[26] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[27] P Maisonneuve,et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[28] C. Griffiths. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. , 1975, National Cancer Institute monograph.